← Back to Search

Spotlight AQ Platform for Type 1 Diabetes

N/A

Recruiting

Led By Mark Clements, MD

Research Sponsored by Children's Mercy Hospital Kansas City

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

16-25 years old

On any diabetes treatment

Must not have

Lack of capacity

<16 years old or >25 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months (approximately)

Awards & highlights

No Placebo-Only Group

Summary

This trial compares a new survey platform called Spotlight AQ to the standard pre-clinic assessment for adolescents and young adults with Type 1 Diabetes. It aims to see if using the Spotlight AQ survey can help

Who is the study for?

This trial is for young people aged 16-25 with Type 1 Diabetes. Participants will use the Spotlight AQ survey before two standard clinic visits and provide feedback on their experience.

What is being tested?

The study is testing if the Spotlight AQ survey platform can improve A1c levels compared to usual care in young diabetics. It also evaluates user satisfaction from both patients and healthcare providers.

What are the potential side effects?

Since this trial involves a survey tool rather than a medical treatment, there are no direct physical side effects expected from participating.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 16 and 25 years old.

Select...

I am currently receiving treatment for diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to make my own medical decisions.

Select...

I am either younger than 16 or older than 25.

Select...

My mental health allows me to fully participate in a study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months (approximately)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months (approximately)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months (approximately) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HbA1c

Secondary study objectives

HCP satisfaction with the Spotlight survey

Participant satisfaction

T1D outcomes

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention (Spotlight AQ)Experimental Treatment1 Intervention

Spotlight AQ is an Artificial Intelligence (AI) powered adaptive survey which identifies the main concerns and gaps in patients tailored to their specific needs in preparation for clinic visits

Group II: Standard of CareActive Control1 Intervention

The pre-clinic survey typically given to patients before clinic visits at each institution

0 / 5Eligibility criteria met